{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T14:09:08Z","timestamp":1795183748264,"version":"4.10.3"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI 107731"],"award-info":[{"award-number":["AI 107731"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI 106695"],"award-info":[{"award-number":["AI 106695"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The four dengue virus serotypes co-circulate globally and cause significant human disease. Dengue vaccine development is challenging because some virus-specific antibodies are protective, while others are implicated in enhanced viral replication and more severe disease. Current dengue tetravalent vaccines contain four live attenuated serotypes formulated to theoretically induce balanced protective immunity. Among the number of vaccine candidates in clinical trials, only Dengvaxia is licensed for use in DENV seropositive individuals. To simplify live-virus vaccine design, we identify co-evolutionary constraints inherent in flavivirus virion assembly and design chimeric viruses to replace domain II (EDII) of the DENV2 envelope (E) glycoprotein with EDII from DENV4. The chimeric DENV2\/4EDII virus replicates efficiently in vitro and in vivo. In male macaques, a single inoculation of DENV2\/4EDII induces type-specific neutralizing antibodies to both DENV2 and DENV4, thereby providing a strategy to simplify DENV vaccine design by utilizing a single bivalent E glycoprotein immunogen for two DENV serotypes.<\/jats:p>","DOI":"10.1038\/s41467-023-36702-x","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T12:56:17Z","timestamp":1678712177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A live dengue virus vaccine carrying a chimeric envelope glycoprotein elicits dual DENV2-DENV4 serotype-specific immunity"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6520-0490","authenticated-orcid":false,"given":"Ellen","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyd","family":"Yount","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petraleigh","family":"Pantoja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Henein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita M.","family":"Meganck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"McBride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Munt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Baric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Scobey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7582-8396","authenticated-orcid":false,"given":"Longping V.","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melween I.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando G.","family":"Burgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravinda","family":"DeSilva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7535-4303","authenticated-orcid":false,"given":"Carlos A.","family":"Sariol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6827-8701","authenticated-orcid":false,"given":"Ralph S.","family":"Baric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,13]]},"reference":[{"key":"36702_CR1","doi-asserted-by":"crossref","unstructured":"de Silva, A. M. & Harris, E. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials. Cold Spring Harb. Perspect. Biol. 10, a029371 (2018).","DOI":"10.1101\/cshperspect.a029371"},{"key":"36702_CR2","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.cell.2015.07.005","volume":"162","author":"MS Diamond","year":"2015","unstructured":"Diamond, M. S. & Pierson, T. C. Molecular Insight into Dengue Virus Pathogenesis and Its Implications for Disease Control. Cell 162, 488\u2013492 (2015).","journal-title":"Cell"},{"key":"36702_CR3","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nature12060","volume":"496","author":"S Bhatt","year":"2013","unstructured":"Bhatt, S. et al. The global distribution and burden of dengue. Nature 496, 504\u2013507 (2013).","journal-title":"Nature"},{"key":"36702_CR4","first-page":"24","volume":"243","author":"SB Halstead","year":"1973","unstructured":"Halstead, S. B., Chow, J. S. & Marchette, N. J. Immunological enhancement of dengue virus replication. Nat. N. Biol. 243, 24\u201326 (1973).","journal-title":"Nat. N. Biol."},{"key":"36702_CR5","doi-asserted-by":"publisher","first-page":"e0005554","DOI":"10.1371\/journal.pntd.0005554","volume":"11","author":"B Patel","year":"2017","unstructured":"Patel, B. et al. Dissecting the human serum antibody response to secondary dengue virus infections. PLoS Negl. Trop. Dis. 11, e0005554 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"36702_CR6","doi-asserted-by":"publisher","first-page":"e1004386","DOI":"10.1371\/journal.ppat.1004386","volume":"10","author":"R de Alwis","year":"2014","unstructured":"de Alwis, R. et al. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathog. 10, e1004386 (2014).","journal-title":"PLoS Pathog."},{"key":"36702_CR7","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1126\/science.aan6836","volume":"358","author":"LC Katzelnick","year":"2017","unstructured":"Katzelnick, L. C. et al. Antibody-dependent enhancement of severe dengue disease in humans. Science 358, 929\u2013932 (2017).","journal-title":"Science"},{"key":"36702_CR8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41586-018-0157-4","volume":"557","author":"H Salje","year":"2018","unstructured":"Salje, H. et al. Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. Nature 557, 719\u2013723 (2018).","journal-title":"Nature"},{"key":"36702_CR9","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1093\/oxfordjournals.aje.a113932","volume":"120","author":"N Sangkawibha","year":"1984","unstructured":"Sangkawibha, N. et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand.I.The 1980 outbreak. Am. J. Epidemiol. 120, 653\u2013669 (1984).","journal-title":"Am. J. Epidemiol."},{"key":"36702_CR10","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1126\/science.aaf9590","volume":"353","author":"NM Ferguson","year":"2016","unstructured":"Ferguson, N. M. et al. Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment. Science 353, 1033\u20131036 (2016).","journal-title":"Science"},{"key":"36702_CR11","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/S1473-3099(18)30494-8","volume":"19","author":"A Wilder-Smith","year":"2019","unstructured":"Wilder-Smith, A. et al. Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine. Lancet Infect. Dis. 19, e31\u2013e38 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"36702_CR12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/ni.3058","volume":"16","author":"W Dejnirattisai","year":"2015","unstructured":"Dejnirattisai, W. et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat. Immunol. 16, 170\u2013177 (2015).","journal-title":"Nat. Immunol."},{"key":"36702_CR13","doi-asserted-by":"crossref","unstructured":"Nivarthi, U. K. et al. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination. J. Virol. 91, e02041\u201316 (2017).","DOI":"10.1128\/JVI.02041-16"},{"key":"36702_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1126\/science.aaa8651","volume":"349","author":"G Fibriansah","year":"2015","unstructured":"Fibriansah, G. et al. DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science 349, 88\u201391 (2015).","journal-title":"Science"},{"key":"36702_CR15","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.chom.2020.04.007","volume":"27","author":"E Young","year":"2020","unstructured":"Young, E. et al. Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies. Cell Host Microbe 27, 710\u2013724 e717 (2020).","journal-title":"Cell Host Microbe"},{"key":"36702_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/1743-422X-8-333","volume":"8","author":"S Zhang","year":"2011","unstructured":"Zhang, S. et al. Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice. Virol. J. 8, 333 (2011).","journal-title":"Virol. J."},{"key":"36702_CR17","doi-asserted-by":"publisher","first-page":"e1006934","DOI":"10.1371\/journal.ppat.1006934","volume":"14","author":"EN Gallichotte","year":"2018","unstructured":"Gallichotte, E. N. et al. Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes. PLoS Pathog. 14, e1006934 (2018).","journal-title":"PLoS Pathog."},{"key":"36702_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21384-0","volume":"12","author":"UK Nivarthi","year":"2021","unstructured":"Nivarthi, U. K. et al. A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans. Nat. Commun. 12, 1102 (2021).","journal-title":"Nat. Commun."},{"key":"36702_CR19","doi-asserted-by":"publisher","first-page":"e0009258","DOI":"10.1371\/journal.pntd.0009258","volume":"15","author":"LJ White","year":"2021","unstructured":"White, L. J. et al.Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003).PLoS Negl Trop Dis. 15, e0009258 (2021).","journal-title":"PLoS Negl Trop Dis."},{"key":"36702_CR20","doi-asserted-by":"publisher","first-page":"e00380","DOI":"10.1128\/mSphere.00380-16","volume":"2","author":"EN Gallichotte","year":"2017","unstructured":"Gallichotte, E. N. et al. Epitope Addition and Ablation via Manipulation of a Dengue Virus Serotype 1 Infectious Clone. mSphere 2, e00380\u201316 (2017).","journal-title":"mSphere"},{"key":"36702_CR21","doi-asserted-by":"publisher","first-page":"e01461","DOI":"10.1128\/mBio.01461-15","volume":"6","author":"EN Gallichotte","year":"2015","unstructured":"Gallichotte, E. N. et al. A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies. MBio 6, e01461\u201301415 (2015).","journal-title":"MBio"},{"key":"36702_CR22","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1093\/infdis\/jiy063","volume":"217","author":"JA Swanstrom","year":"2018","unstructured":"Swanstrom, J. A. et al. Analyzing the Human Serum Antibody Responses to a Live Attenuated Tetravalent Dengue Vaccine Candidate. J. Infect. Dis. 217, 1932\u20131941 (2018).","journal-title":"J. Infect. Dis."},{"key":"36702_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/infdis\/jiz109","volume":"220","author":"JA Swanstrom","year":"2019","unstructured":"Swanstrom, J. A. et al. Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines. J. Infect. Dis. 220, 219\u2013227 (2019).","journal-title":"J. Infect. Dis."},{"key":"36702_CR24","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","volume":"381","author":"S Biswal","year":"2019","unstructured":"Biswal, S. et al. Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents. N. Engl. J. Med. 381, 2009\u20132019 (2019).","journal-title":"N. Engl. J. Med"},{"key":"36702_CR25","doi-asserted-by":"publisher","first-page":"100155","DOI":"10.1016\/j.xcrm.2020.100155","volume":"1","author":"HA Tu","year":"2020","unstructured":"Tu, H. A. et al. Stimulation of B Cell Immunity in Flavivirus-Naive Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003. Cell Rep. Med. 1, 100155 (2020).","journal-title":"Cell Rep. Med"},{"key":"36702_CR26","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa1800820","volume":"379","author":"S Sridhar","year":"2018","unstructured":"Sridhar, S. et al. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. N. Engl. J. Med 379, 327\u2013340 (2018).","journal-title":"N. Engl. J. Med"},{"key":"36702_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/cid\/ciab864","volume":"75","author":"L Rivera","year":"2022","unstructured":"Rivera, L. et al. Three-year Efficacy and Safety of Takeda\u2019s Dengue Vaccine Candidate (TAK-003). Clin. Infect. Dis. 75, 107\u2013117 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"36702_CR28","doi-asserted-by":"publisher","first-page":"7700","DOI":"10.1128\/JVI.00197-13","volume":"87","author":"VA Kostyuchenko","year":"2013","unstructured":"Kostyuchenko, V. A., Zhang, Q., Tan, J. L., Ng, T. S. & Lok, S. M. Immature and mature dengue serotype 1 virus structures provide insight into the maturation process. J. Virol. 87, 7700\u20137707 (2013).","journal-title":"J. Virol."},{"key":"36702_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/srep00261","volume":"2","author":"S Tian","year":"2012","unstructured":"Tian, S., Huajun, W. & Wu, J. Computational prediction of furin cleavage sites by a hybrid method and understanding mechanism underlying diseases. Sci. Rep. 2, 261 (2012).","journal-title":"Sci. Rep."},{"key":"36702_CR30","doi-asserted-by":"publisher","first-page":"e0038622","DOI":"10.1128\/mbio.00386-22","volume":"13","author":"LV Tse","year":"2022","unstructured":"Tse, L. V. et al. Generation of Mature DENVs via Genetic Modification and Directed Evolution. mBio 13, e0038622 (2022).","journal-title":"mBio"},{"key":"36702_CR31","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1083\/jcb.200806081","volume":"183","author":"R Fritz","year":"2008","unstructured":"Fritz, R., Stiasny, K. & Heinz, F. X. Identification of specific histidines as pH sensors in flavivirus membrane fusion. J. Cell Biol. 183, 353\u2013361 (2008).","journal-title":"J. Cell Biol."},{"key":"36702_CR32","doi-asserted-by":"publisher","first-page":"12233","DOI":"10.1128\/JVI.00247-14","volume":"88","author":"SA Smith","year":"2014","unstructured":"Smith, S. A. et al. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. J. Virol. 88, 12233\u201312241 (2014).","journal-title":"J. Virol."},{"key":"36702_CR33","doi-asserted-by":"publisher","first-page":"e00440","DOI":"10.1128\/JVI.00440-18","volume":"92","author":"V Barban","year":"2018","unstructured":"Barban, V. et al. Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and \u22124. J. Virol. 92, e00440\u201318 (2018).","journal-title":"J. Virol."},{"key":"36702_CR34","doi-asserted-by":"publisher","first-page":"978","DOI":"10.4269\/ajtmh.2011.10-0592","volume":"84","author":"JE Osorio","year":"2011","unstructured":"Osorio, J. E. et al. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques. Am. J. Trop. Med Hyg. 84, 978\u2013987 (2011).","journal-title":"Am. J. Trop. Med Hyg."},{"key":"36702_CR35","doi-asserted-by":"publisher","first-page":"e147066","DOI":"10.1172\/JCI147066","volume":"131","author":"S Henein","year":"2021","unstructured":"Henein, S. et al. Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection. J. Clin. Invest 131, e147066 (2021).","journal-title":"J. Clin. Invest"},{"key":"36702_CR36","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1073\/pnas.1812055115","volume":"116","author":"R Raut","year":"2019","unstructured":"Raut, R. et al. Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies. Proc. Natl Acad. Sci. USA 116, 227\u2013232 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"36702_CR37","doi-asserted-by":"publisher","first-page":"4659","DOI":"10.1016\/j.vaccine.2017.07.045","volume":"35","author":"LC Katzelnick","year":"2017","unstructured":"Katzelnick, L. C. & Harris, E., Participants in the Summit on Dengue Immune Correlates of, P. Immune correlates of protection for dengue: State of the art and research agenda. Vaccine 35, 4659\u20134669 (2017).","journal-title":"Vaccine"},{"key":"36702_CR38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/978-981-10-8727-1_5","volume":"1062","author":"EN Gallichotte","year":"2018","unstructured":"Gallichotte, E. N., Baric, R. S. & de Silva, A. M. The Molecular Specificity of the Human Antibody Response to Dengue Virus Infections. Adv. Exp. Med Biol. 1062, 63\u201376 (2018).","journal-title":"Adv. Exp. Med Biol."},{"key":"36702_CR39","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.celrep.2018.10.006","volume":"25","author":"EN Gallichotte","year":"2018","unstructured":"Gallichotte, E. N. et al. Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and Neutralization. Cell Rep. 25, 1214\u20131224 (2018).","journal-title":"Cell Rep."},{"key":"36702_CR40","doi-asserted-by":"publisher","first-page":"855","DOI":"10.4269\/ajtmh.20-0042","volume":"103","author":"AP Durbin","year":"2020","unstructured":"Durbin, A. P. et al. Immunogenicity and Safety of a Tetravalent Recombinant Subunit Dengue Vaccine in Adults Previously Vaccinated with a Live Attenuated Tetravalent Dengue Vaccine: Results of a Phase-I Randomized Clinical Trial. Am. J. Trop. Med Hyg. 103, 855\u2013863 (2020).","journal-title":"Am. J. Trop. Med Hyg."},{"key":"36702_CR41","unstructured":"Takeda. Takeda\u2019s QDENGA\u00ae\u25bc (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure. (Takeda Newsroom, 2022). https:\/\/www.takeda.com\/newsroom\/newsreleases\/2022\/takedas-qdenga-dengue-tetravalent-vaccine-live-attenuated-approved-in-indonesia-for-use-regardless-of-prior-dengue-exposure\/."},{"key":"36702_CR42","unstructured":"Institute, B. Butantan\u2019s dengue vaccine has 79.6% efficacy, partial results from 2-year follow-up show. (Portal do Butantan, 2022). https:\/\/butantan.gov.br\/noticias\/butantan%27s-dengue-vaccine-has-79.6-efficacy-partial-results-from-2-year-follow-up-show."},{"key":"36702_CR43","doi-asserted-by":"publisher","first-page":"eabg4084","DOI":"10.1126\/sciadv.abg4084","volume":"7","author":"ST Kudlacek","year":"2021","unstructured":"Kudlacek, S. T. et al. Designed, highly expressing, thermostable dengue virus 2 envelope protein dimers elicit quaternary epitope antibodies. Sci. Adv. 7, eabg4084 (2021).","journal-title":"Sci. Adv."},{"key":"36702_CR44","doi-asserted-by":"publisher","first-page":"e00745","DOI":"10.1128\/JVI.00745-20","volume":"94","author":"A Thomas","year":"2020","unstructured":"Thomas, A. et al. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus. J. Virol. 94, e00745\u201320 (2020).","journal-title":"J. Virol."},{"key":"36702_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-97038-4","volume":"11","author":"T Imagawa","year":"2021","unstructured":"Imagawa, T. et al. Virus-like particles with FLAG-tagged envelope protein as a tetravalent dengue vaccine candidate. Sci. Rep. 11, 17542 (2021).","journal-title":"Sci. Rep."},{"key":"36702_CR46","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1126\/science.abi4506","volume":"373","author":"DR Martinez","year":"2021","unstructured":"Martinez, D. R. et al. Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Science 373, 991\u2013998 (2021).","journal-title":"Science"},{"key":"36702_CR47","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4049\/immunohorizons.1900022","volume":"3","author":"A Choi","year":"2019","unstructured":"Choi, A. et al. Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice. Immunohorizons 3, 133\u2013148 (2019).","journal-title":"Immunohorizons"},{"key":"36702_CR48","doi-asserted-by":"publisher","first-page":"e1486","DOI":"10.1371\/journal.pntd.0001486","volume":"6","author":"WB Messer","year":"2012","unstructured":"Messer, W. B. et al. Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization. PLoS Negl. Trop. Dis. 6, e1486 (2012).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"36702_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17355-5","volume":"7","author":"DG Widman","year":"2017","unstructured":"Widman, D. G. et al. Transplantation of a quaternary structure neutralizing antibody epitope from dengue virus serotype 3 into serotype 4. Sci. Rep. 7, 17169 (2017).","journal-title":"Sci. Rep."},{"key":"36702_CR50","doi-asserted-by":"publisher","first-page":"e01123","DOI":"10.1128\/mBio.01123-16","volume":"7","author":"JA Swanstrom","year":"2016","unstructured":"Swanstrom, J. A. et al. Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus. MBio 7, e01123\u201316 (2016).","journal-title":"MBio"},{"key":"36702_CR51","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1128\/JCM.00827-07","volume":"45","author":"AA Kraus","year":"2007","unstructured":"Kraus, A. A., Messer, W., Haymore, L. B. & de Silva, A. M. Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization. J. Clin. Microbiol 45, 3777\u20133780 (2007).","journal-title":"J. Clin. Microbiol"},{"key":"36702_CR52","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.physbeh.2011.03.023","volume":"103","author":"MA Taffe","year":"2011","unstructured":"Taffe, M. A. A comparison of intraperitoneal and subcutaneous temperature in freely moving rhesus macaques. Physiol. Behav. 103, 440\u2013444 (2011).","journal-title":"Physiol. Behav."},{"key":"36702_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15674","volume":"8","author":"P Pantoja","year":"2017","unstructured":"Pantoja, P. et al. Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus. Nat. Commun. 8, 15674 (2017).","journal-title":"Nat. Commun."},{"key":"36702_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12295-2","volume":"10","author":"EX Perez-Guzman","year":"2019","unstructured":"Perez-Guzman, E. X. et al. Time elapsed between Zika and dengue virus infections affects antibody and T cell responses. Nat. Commun. 10, 4316 (2019).","journal-title":"Nat. Commun."},{"key":"36702_CR55","doi-asserted-by":"publisher","first-page":"e0008285","DOI":"10.1371\/journal.pntd.0008285","volume":"14","author":"C Serrano-Collazo","year":"2020","unstructured":"Serrano-Collazo, C. et al. Effective control of early Zika virus replication by Dengue immunity is associated to the length of time between the 2 infections but not mediated by antibodies. PLoS Negl. Trop. Dis. 14, e0008285 (2020).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"36702_CR56","first-page":"351","volume":"215","author":"S Henein","year":"2017","unstructured":"Henein, S. et al. Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals. J. Infect. Dis. 215, 351\u2013358 (2017).","journal-title":"J. Infect. Dis."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36702-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36702-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36702-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T12:56:55Z","timestamp":1678712215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36702-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,13]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["36702"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-36702-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,13]]},"assertion":[{"value":"10 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.S.B. and A.d.S. have served as consultants for Takeda Vaccines and Sanofi Pasteur. R.S.B. is on the advisory board of Adagio Therapeutics and VaxArt. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1371"}}